Pharmaceutical

Our goal is to help companies reduce cost per cubic met...

The pharma industry is considered one of the most polluting industries, not jus...

Amneal unveils new brand to reimagine what’s possible i...

Amneal Pharmaceuticals introduced a bold new brand and visual identity that ref...

Next big leap in Indian pharma’s digital journey, AI-le...

Archimedis Digital, a leading digital transformation partner for life sciences ...

India’s Pharma 2047: How academia can drive innovation ...

As India marches toward its 2047 vision of becoming an innovation-led, self-rel...

Atara receives FDA complete response letter for Ebvallo...

The application sought approval for Ebvallo as monotherapy in adult and paediatr...

SciNeuro and Novartis sign global licensing deal for Al...

The agreement will leverage SciNeuro’s proprietary blood-brain barrier shuttle t...

Clinical research careers: India’s next big opportunity

With the global healthcare and life sciences sector set to cross USD 4.28 billi...

Bionpharma receives US FDA approval for Etravirine tabl...

Marking a significant milestone in the global effort to expand access to advanc...

The next wave of growth will belong not to the fastest ...

As India moves into 2026, industry experts state that the next phase of growth ...

Hongene Biotech announces grant to expand global access...

Hongene Biotech announced the receipt of a grant from the Gates Foundation to d...

Jubilant Biosys doubles early chemistry scale-up capaci...

 Jubilant Biosys, a wholly owned subsidiary of Jubilant Pharmova, and a global ...

AAPI, Cadila Pharma host forum on Ayurveda’s role as an...

The American Association of Physicians of Indian Origin (AAPI), in collaboratio...

Alembic Pharmaceuticals receives USFDA tentative approv...

Alembic  Pharmaceuticals announced that it has received tentative approval from...

MediLink and Roche announce exclusive licensing agreeme...

Under the agreement, MediLink will receive upfront and near-term milestone payme...

Novartis to build fourth US radioligand therapy facilit...

The facility forms a key component of the company’s $23bn US investment programm...

We train professionals to see quality not as a checklis...

How does IGMPI’s training ecosystem directly address the root causes of patient...